If you are struggling with a late-stage or complex form of cancer, Envita Medical Centers and our proprietary
oncology
technology may be the alternative solution you have been looking for. Envita is a Center of Excellence for precision
oncology and we are extremely familiar with the problems many patients face when pursuing cancer treatment. We know
that there is a better way to treat cancer and for the last 20 years we have been using personalized genetically
driven therapies to give our patients the best chance to respond favorably. In that time, we have developed many
advanced forms of treatment and chemotherapy including a state-of-the-art chemotherapy program we call GTFC™ or
Genetically Targeted Fractionated Chemotherapy.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
GTFC™ is our proprietary form of low-dose fractionated chemotherapy that can hit up to 7-10 genetic biomarkers and
mechanisms of tumor kill at once, something traditional chemotherapy simply cannot do. Furthermore, GTFC™ is
specifically designed to ensure that the majority of our patients experience minimal side-effects due to the
utilization of metronomic/low dosing. Through cutting-edge technology, we can precision target your cancer treatment
and provide chemotherapy that goes far beyond what most other clinics in the nation can provide. GTFC™ is uniquely
designed for each individual patient and is created in our in-house pharmacy ensuring that each treatment is
personalized and customized to the patient’s genetic targets.
Traditional chemotherapy is a taxing and destructive treatment that can be as harmful as the cancer it is meant to
treat when not properly targeted, at Envita we take a more advanced approach by combining GTFC™ with research-based
natural intravenous therapies, immunotherapies, and many other world-class treatments to provide a multifaceted
approach to treating cancer.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
GTFC™ and the NCCN
We believe Genetically Targeted Fractionated Chemotherapy to be the future of personalized cancer treatment. The
current standard approach to oncology prescribes chemotherapies based on tissue stage and location derived from the
NCCN guidelines. The NCCN (National Comprehensive Cancer Network) is defined as an alliance of 28 cancer centers
aiming to use a multidisciplinary team approach to patient care in order to help select the best treatment options for
a specific type and stage of cancer. However, these regimens are collated from data and clinical information taken
from large clinical trials that try to find the best treatment for the largest percentage of the population with the
same type and stage of cancer. Unfortunately, using this method alone is a flawed and outdated approach for
establishing cancer treatment options in our clinical opinion. Fortunately, Envita goes beyond the NCCN guidelines by
personalizing care for our patients based on advanced cancer genetic profiles. The genetic testing offered at Envita
for our GTFC™ process is far more detailed than other common cancer genetic profiles that are commonly available. The
advanced genetic profiles offered to our patients provide an advantage to potentially achieve more accurate and
targeted treatments, especially when other treatment options have failed the patient. Envita Medical Centers has been
specializing in treating late-stage cancer for nearly 20 years. We base our treatments on patient specific advanced
genetic targets, molecular profiles, and biomarkers, giving our patients the best chances to achieve remission. The
GTFC™ process starts with great testing, but that is just the beginning to our process.
Next-Generation Personalized Genetic Information
Next-generation personalized genetic information is the bases for GTFC™ and that means identifying biomarkers that we
can target during your treatment[1]. For those who do not know, biomarkers and other molecular targets are gathered
from your metastasized cancerous cells. These metastatic cells contain valuable information that we use to, among
other things, determine what chemotherapy agents and integrative agents that will work best for each specific
patient[1]. We utilize cutting-edge technology to gather the necessary genetic information in a non-invasive and
efficient way. Instead of doing an aggressive tumor biopsy which can provide outdated data, we use circulating cancer
cells, and free-floating DNA because they represent the most current form of your ever-changing disease[1].
Circulating cancer cells can be gathered through a simple blood draw and genetic information can be updated throughout
treatment to evaluate progress and reassess therapy to keep the protocol dynamic[2]. We gather your circulating cancer
cells and other genetic and nutritional information to perform intensely in-depth testing to get a cornucopia of data
on you and your cancer. This data becomes the driving force behind how we build a personalized treatment protocol for
you. Our proprietary testing is among the best in the nation and our ability to identify, track, and modulate the
genetic factors of your cancer is second to none. In our opinion, our experience and advanced methods makes us one of
the best treatment centers in the nation for late-stage and complex cancers.
With up-to-date genetic profiles on you and your cancer, we design GTFC™ to use the chemotherapy agents that are
scientifically found to be best for combatting your unique cancer[1]. We test your cancer cells against a multitude of
different chemotherapy drugs to find the medications that are the most likely to be effective at hitting your cancer
cell
biomarkers. Cancer cell antigen biomarkers are the gate-keepers of the cell and finding the chemotherapies that are
best suited to target your cancer cell antigen biomarkers is how the chemotherapy agent is going to target and
infiltrate your cancerous cells. By matching the chemotherapy to your cancer antigen biomarkers, we improve the
ability to target the cancerous cells and ignore healthy cells[3]. With this information we can utilize our in-house
pharmacy Vertisis Custom Pharmacy to create a GTFC™ that is custom compounded to utilize the most efficacious
chemotherapy based on your cancer’s genetic targets. This is combined with a multifaceted protocol that uses
genetically targeted natural medicines, immunotherapies, and epigenetic factors.
GTFC™'s Targeting Method
Targeting our care is the key to properly attacking your cancer and it is meant to stack the odds in favor of our
patients and help overcome multidrug resistance (MDR). We use many different types of biomarkers to identify and
target your cancer. We look at cancer antigen biomarkers, metabolic biomarkers, epigenetic biomarkers (miRNA), genetic
biomarkers, immunotherapy markers and chromosomal biomarkers[1] to guide and genetically target our personalized
treatment protocols and GTFC™. We found clinically that genetically targeted care is a much more effective and precise
approach to treating cancer and, in concert with therapeutic windows induced by natural and integrative medicines, it
allows us to focus care and use fractionated doses of chemo agents that are far less than the normal doses used in
standard chemotherapy. The standardized method of chemotherapy uses the maximum therapeutic dose which is a fancy way
of saying they give you as much poison as they can in hopes that it kills the cancer cells before it harms you. Envita
sees the obvious flaw in this method and we designed GTFC™ to be precise and effective while reduced damage to healthy
cells. By utilizing fractionated doses and combining that with targeted natural therapies, immune recovery, smart
drugs, and phytotherapeutics we remove many of the major side-effects normally experienced during chemotherapy. We
work to make patients therapy as comfortable and effective as possible while undoing the negative repercussions from
past treatments.
Furthermore, these microdoses allow us to hit many more biomarkers and mechanisms of tumor kill at once than normal
chemotherapy in addition to decreasing the major side-effects caused by chemotherapy agents. Our method is so precise
and effective we do not need the maximum therapeutic dose to treat cancer. We can take microdoses of multiple chemo
agents at once and combine them in our in-house pharmacy Vertisis Custom Pharmacy to produce a customized medication
designed, combined, and produced to combat your unique cancer. We hit from 7-10 biomarkers at once and increase the
frequency of treatment to try and remove cancers ability to resist treatment.
GTFC™’s Superior Absorption
The final component of GTFC™ is increased absorption. Normal intravenous chemotherapy treatment only gets an
estimated
4-5% of the agents absorbed into the cancerous cells, but at Envita our goal is to get closer to a 100% absorption
into cancerous cells. Envita Medical Centers uses cutting-edge natural therapies and techniques to increase the
absorption of chemotherapy during GTFC™. We have been very successful using these techniques in the past but Envita’s
goal is for a complete 100% absorption while protecting healthy cells and that is why in some cases we utilize an
intratumoral GTFC™ that allows for image guided injections of these genetic and immunologic drugs directly into the
tumor. In cancers that have very fibrous and dense tissues around tumors we deploy a combination of cryoablation and
intra-tumor deployment of GTFC™. this usually allows for an immediate kill at the tumor level to help our patients.
GTFC™ is
an
exciting advanced approach to potentially achieve better cancer outcomes for our patients. Envita is constantly
researching and improving our techniques to give our patients that greatest chance to respond to care. That is why we
developed GTFC™ and that is why we continue to refine and grow our tools for fighting against cancer. The vast
majority
of our patients are always impressed and excited to see the options Envita can provide, as well as to learn why their
previous treatment plans didn’t respond as well as they had hoped. Our patients are excited to have a world-class
treatment plan where they can feel confident about their care.
Envita Medical Centers has been treating late-stage and complex cancers for nearly 20 years and GTFC™ has been
instrumental in providing our patients the most up to date and effective care. We know the struggles and problems of
high-dose and protocol-driven chemotherapy treatments and we are fighting to provide as many patients as we can relief
from those shortcomings. GTFC™ is a highly specialized method for treating cancer and we believe it is the future of
personalized integrative cancer treatment. If you are looking for a better approach to treating you or your loved
one’s cancer, please contact our Patient Care Coordinators at 866-830-4576 and learn more about our treatment options.
References
[1] Smith, A.J., J. Oertle, and D. Prato, Genetically Targeted Fractionated Chemotherapy. Journal of Cancer
Therapy, 2015. Vol.06No.02: p. 17.
[2] Arnold, K., MEMORANDUM FOR: Science Writers and Editors on the Journal Press List: Biomarker for Esophageal
Cancer Found in Bloodstream. Journal of the National Cancer Institute, 2000. 92(22): p. 1787b-1787.
[3] Ludwig, J.A. and J.N. Weinstein, Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nature
Reviews Cancer, 2005. 5: p. 845
Choose Envita Medical Centers
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.